Real Life Clinical Practice, Multicenter Study Of Ixazomib Based First Line Therapy Comparing Efficacy And Safety Profile With Reported Data In Randomised Clinical Trials In China
Latest Information Update: 27 Oct 2020
At a glance
- Drugs Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone; Doxorubicin; Lenalidomide; Thalidomide
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 01 Nov 2020 Results published in the Annals of Hematology
- 12 Dec 2019 New trial record
- 10 Dec 2019 Results (n=60), Comparing efficacy and safety of Ixazomib as a first line therapy data with already reported data from randomized clinical trial in Chinese patients with newly diagnosed Multiple Myeloma, presented at the 61st Annual Meeting and Exposition of the American Society of Hematology